CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
基于 CAR-T 细胞的肿瘤细胞治疗：简介与印度视角
英文原题：Chimeric Antigen Receptor T-cell based cellular therapies for cancer: An introduction and Indian perspective.
查看英文原题
Chimeric Antigen Receptor T-cell based cellular therapies for cancer: An introduction and Indian perspective.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
利用自身免疫系统治疗癌症一直是癌症生物学和治疗学中的一个活跃研究领域。细胞免疫治疗中的一种机会是过继性细胞转移。随着CAR-T 疗法最近被批准用于癌症治疗，癌症治疗的全新范式已经开启，为复发/难治性癌症患者带来了一线希望。尽管临床结果令人鼓舞，但该疗法仍处于早期阶段，并且由于其高昂的成本和物流挑战，大多数患者仍然无法获得。在印度，这些疗法尚不可用，并且因经济挑战和庞大的人口而进一步加剧。在这篇综述中，我们讨论了T细胞免疫治疗的各个方面，特别关注CAR-T 在印度情境下的情况。我们涉及CAR-T 细胞疗法的基础科学方面、作用机制、生产、临床方面和商业方面，以及其在全球和印度的未来。
展开英文摘要原文
Using one's own immune system for curing cancer has been an active field of research in cancer biology and therapeutics. One such opportunity in cellular immunotherapy is adoptive cell transfers. With the recent approval of CAR-T therapy as a cancer treatment, a whole new paradigm of cancer treatment has opened-up, with a ray of hope for relapsed/refractory cancer patients.
Despite promising clinical outcomes, the therapy is in its early phase and remains out of reach for most patients due to its high cost and logistic challenges. In India, these therapies are unavailable and further confounded by the economic challenges and a large population. In this review, we discuss various aspects of T-cell immunotherapies with a special focus on CAR-T in the Indian scenario.
We touch upon the basic scientific aspects, mechanism of action, manufacturing, clinical aspects and commercial aspects of the CAR-Tcell therapies and its future worldwide and in India.
论文信息
- 作者
- Rathod RJ、Sukumaran RK、Kedia N、Kumar J、Nair R、Chandy M、Gandikota L、Radhakrishnan VS
- 第一作者单位
- Cell and Gene Therapy Division, Intas Pharmaceuticals, Ahmedabad, Gujarat, India.India
- 通讯作者单位
- Hematology Oncology and HCT, Tata Medical Center, Kolkata, West Bengal, India.India
- 文献类型
- 综述
- 期刊
- Indian journal of cancer2024 Apr 1
- 原文标识
- PubMed 39152647 · DOI 10.4103/ijc.ijc_433_21